The Scottish Medicines Consortium (SMC) has granted approval for the usage of Mounjaro, also known as tirzepatide, as a treatment for individuals grappling with type 2 diabetes in Scotland. This sanction closely follows the announcement made by NHS England in March, extending the availability of Mounjaro as a treatment option for type 2 diabetes or as an alternative for those unable to access their customary GLP-1 RA medication.
Persistent supply challenges with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are anticipated to persist until late 2024, exacerbating the shortage of medications such as Ozempic and Trulicity. In response to these shortages, Mounjaro is now being offered as an option for individuals in England encountering difficulties in obtaining Ozempic, Trulicity, or other GLP-1 RA medications.
While the approval for Mounjaro marks a positive stride for individuals with type 2 diabetes, concerns linger regarding the intermittent supply and ongoing shortages of GLP-1 medications, which continue to impact numerous patients.
Manufactured by Eli Lilly, Mounjaro is a GLP-1 analogue combined with a GIP analogue and is administered through once-weekly injections. Its mechanism involves activating both GLP-1 and GIP receptors to bolster incretin levels in the body, thereby enhancing insulin production and reducing glucose production by the liver, ultimately leading to decreased blood glucose levels.
Research into tirzepatide’s efficacy in managing type 2 diabetes has revealed promising outcomes, demonstrating greater improvements in blood glucose management and weight loss compared to other medications. NICE has recommended Mounjaro as an alternative for adults with type 2 diabetes, particularly those with a BMI of 35kg/m2 or higher and experiencing additional psychological or medical complications.
Presently, Mounjaro is available for prescription in England, Wales, and Northern Ireland, facilitated by approvals from NICE and the SMC. The medication is offered in a multi-dose version named Mounjaro Kwikpen, providing lower strengths for injections, with higher strengths anticipated later this year.
While efforts are ongoing to address GLP-1 RA supply issues and ensure access to essential medications for individuals with type 2 diabetes, it’s imperative to acknowledge that Mounjaro, like all medications, may induce side effects. These include nausea, indigestion, constipation, diarrhea, pancreatitis, and gallstones. Individuals considering tirzepatide treatment should seek personalized advice from their healthcare provider and promptly report any experienced side effects during treatment.